NASDAQ:CELC - US15102K1007 - Common Stock
The current stock price of CELC is 51.23 USD. In the past month the price increased by 28.36%. In the past year, price increased by 220.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.87 | 371.68B | ||
AMGN | AMGEN INC | 13.19 | 154.89B | ||
GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
INSM | INSMED INC | N/A | 28.77B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
NTRA | NATERA INC | N/A | 23.09B | ||
BIIB | BIOGEN INC | 8.26 | 19.38B |
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
CELCUITY INC
16305 36th Ave N Ste 100
Minneapolis MINNESOTA 55446 US
CEO: Brian F. Sullivan
Employees: 87
Phone: 17633920767
The current stock price of CELC is 51.23 USD. The price decreased by -6.17% in the last trading session.
The exchange symbol of CELCUITY INC is CELC and it is listed on the Nasdaq exchange.
CELC stock is listed on the Nasdaq exchange.
14 analysts have analysed CELC and the average price target is 70.82 USD. This implies a price increase of 38.23% is expected in the next year compared to the current price of 51.23. Check the CELCUITY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CELCUITY INC (CELC) has a market capitalization of 2.17B USD. This makes CELC a Mid Cap stock.
CELCUITY INC (CELC) currently has 87 employees.
CELCUITY INC (CELC) has a support level at 49. Check the full technical report for a detailed analysis of CELC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CELC does not pay a dividend.
CELCUITY INC (CELC) will report earnings on 2025-11-12, after the market close.
CELCUITY INC (CELC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.6).
The outstanding short interest for CELCUITY INC (CELC) is 8.89% of its float. Check the ownership tab for more information on the CELC short interest.
ChartMill assigns a technical rating of 9 / 10 to CELC. When comparing the yearly performance of all stocks, CELC is one of the better performing stocks in the market, outperforming 99.32% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to CELC. The financial health of CELC is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CELC reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS decreased by -31.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -81% | ||
ROE | -335.12% | ||
Debt/Equity | 2.24 |
14 analysts have analysed CELC and the average price target is 70.82 USD. This implies a price increase of 38.23% is expected in the next year compared to the current price of 51.23.